Appendix A
Guidelines for Determining the Number of Lines and Duration of Chemotherapy

**Example 1:**
- Vinorelbine → Gemcitabine
  - **Duration:**
  - **Count:** TWO lines
  - **Narrative:** Patient started on vinorelbine and progressed and changed to gemcitabine. Vinorelbine would be considered first line, and gemcitabine would be the second line.
  - **Duration of first line:** Start of vinorelbine to the start of gemcitabine

**Example 2:**
- Vinorelbine → Endocrine therapy → Gemcitabine
  - **Duration:** (No progression) (Progression)
  - **Count:** TWO lines
  - **Narrative:** Patient started on vinorelbine, and switched to endocrine therapy with or without progression on vinorelbine. Patient started on gemcitabine as the second line.
  - **Duration of first line (no progression on vinorelbine):** Start of vinorelbine to the start of gemcitabine
  - **Duration of first line (progression on vinorelbine):** Start of vinorelbine to the start of endocrine therapy

**Example 3:**
- Vinorelbine 1 → Endocrine therapy → Vinorelbine 2 → Chemotherapy
  - **Duration:** (No progression) (If progression)
  - **Count:** (No progression on vinorelbine 1) ONE line (Progression on vinorelbine 1) TWO lines
  - **Narrative:** Patient started on vinorelbine 1, and switched to endocrine therapy without progression. Patient progressed on endocrine therapy and switched back to vinorelbine. Vinorelbine would be considered one line. If the patient experienced progression while on vinorelbine 1, the second time that vinorelbine is given would be considered a second line.
  - **Duration of first line (no progression on vinorelbine 1):** Start of vinorelbine 1 to the start of next chemotherapy
  - **Duration of first line (progression on vinorelbine 1):** Start of vinorelbine 1 to the start of endocrine therapy

**Example 4:**
- Vinorelbine → Trastuzumab → Chemotherapy
  - **Duration:**
  - **Count:** TWO lines
  - **Narrative:** Patient started on monotherapy vinorelbine, and changed to trastuzumab monotherapy with or without progression. Vinorelbine would be considered one line, and trastuzumab would be considered the second line.
  - **Duration of first line (progression):** Start of vinorelbine to the start of trastuzumab

**Example 5:**
- Vinorelbine + Trastuzumab → Trastuzumab → Chemotherapy
  - **Duration:**
  - **Count:** ONE line
  - **Narrative:** Patient started on vinorelbine + trastuzumab then switched to trastuzumab alone with or without progression.
  - **Duration of first line:** Start of vinorelbine + trastuzumab to the start of next chemotherapy
Example 6:

Vinorelbine + Trastuzumab 1 → Trastuzumab → Vinorelbine + Trastuzumab 2 → Chemotherapy

Duration: 

Count: ONE line

Narrative: Patient started on vinorelbine + trastuzumab 1 and switched to trastuzumab alone. No evidence of progression while on vinorelbine + trastuzumab 1. Patient subsequently progresses on trastuzumab alone, and vinorelbine is added back into the regimen. Vinorelbine + trastuzumab 1 and 2 would be considered as one line altogether.

Duration of first line: Start of vinorelbine + trastuzumab to the start of next chemotherapy

Example 7:

Paclitaxel + Trastuzumab → Carboplatin + Paclitaxel + Trastuzumab

Duration: 

Count: TWO lines

Narrative: Patients started on paclitaxel and trastuzumab. Patient progresses and carboplatin is added to the pre-existing regime.

Duration of first line: Start of paclitaxel + trastuzumab to the start of carboplatin + paclitaxel + trastuzumab

Example 8:

Endocrine therapy 1 → Endocrine therapy 2

Count: ZERO lines

Narrative: Patient started on an endocrine agent (eg, tamoxifen). The patient progresses and is switched to another endocrine agent (eg, letrozole). None of the therapies will be counted.

Example 9:

Endocrine therapy + Trastuzumab → Trastuzumab

Count: ZERO lines

Narrative: Patient started on an endocrine agent in combination with trastuzumab. The patient is switched to trastuzumab monotherapy with or without progression. None of the therapies will be counted.

Example 10:

Endocrine therapy → Trastuzumab → Chemotherapy

Duration: 

Count: ONE line

Narrative: Patient started on an endocrine agent and is switched to trastuzumab with or without progression. The endocrine therapy will not be counted, but the trastuzumab will be counted as 1 line.

Duration of first line: Start of trastuzumab to the start of next chemotherapy

Guidelines for Determining the Duration of the Last Line of Chemotherapy

Example 1:

Chemotherapy → Date of last known chemotherapy

Duration: 

Narrative: The duration of the last line is counted as the start of chemotherapy to the date of the last known chemotherapy administration.

Example 2:

Chemotherapy → Endocrine therapy → Date of death/lost to follow up

Duration: 

Narrative: The duration of the last line is counted as the start of chemotherapy to the date of the last known chemotherapy administration regardless of whether the patient had subsequent lines of endocrine therapy.